Cargando…

6E11, a highly selective inhibitor of Receptor-Interacting Protein Kinase 1, protects cells against cold hypoxia-reoxygenation injury

Necroptosis is a programmed cell death pathway that has been shown to be of central pathophysiological relevance in multiple disorders (hepatitis, brain and cardiac ischemia, pancreatitis, viral infection and inflammatory diseases). Necroptosis is driven by two serine threonine kinases, RIPK1 (Recep...

Descripción completa

Detalles Bibliográficos
Autores principales: Delehouzé, C., Leverrier-Penna, S., Le Cann, F., Comte, A., Jacquard-Fevai, M., Delalande, O., Desban, N., Baratte, B., Gallais, I., Faurez, F., Bonnet, M. C., Hauteville, M., Goekjian, P. G., Thuillier, R., Favreau, F., Vandenabeele, P., Hauet, T., Dimanche-Boitrel, M. T., Bach, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635128/
https://www.ncbi.nlm.nih.gov/pubmed/29018243
http://dx.doi.org/10.1038/s41598-017-12788-4
_version_ 1783270223095267328
author Delehouzé, C.
Leverrier-Penna, S.
Le Cann, F.
Comte, A.
Jacquard-Fevai, M.
Delalande, O.
Desban, N.
Baratte, B.
Gallais, I.
Faurez, F.
Bonnet, M. C.
Hauteville, M.
Goekjian, P. G.
Thuillier, R.
Favreau, F.
Vandenabeele, P.
Hauet, T.
Dimanche-Boitrel, M. T.
Bach, S.
author_facet Delehouzé, C.
Leverrier-Penna, S.
Le Cann, F.
Comte, A.
Jacquard-Fevai, M.
Delalande, O.
Desban, N.
Baratte, B.
Gallais, I.
Faurez, F.
Bonnet, M. C.
Hauteville, M.
Goekjian, P. G.
Thuillier, R.
Favreau, F.
Vandenabeele, P.
Hauet, T.
Dimanche-Boitrel, M. T.
Bach, S.
author_sort Delehouzé, C.
collection PubMed
description Necroptosis is a programmed cell death pathway that has been shown to be of central pathophysiological relevance in multiple disorders (hepatitis, brain and cardiac ischemia, pancreatitis, viral infection and inflammatory diseases). Necroptosis is driven by two serine threonine kinases, RIPK1 (Receptor Interacting Protein Kinase 1) and RIPK3, and a pseudo-kinase MLKL (Mixed Lineage Kinase domain-Like) associated in a multi-protein complex called necrosome. In order to find new inhibitors for use in human therapy, a chemical library containing highly diverse chemical structures was screened using a cell-based assay. The compound 6E11, a natural product derivative, was characterized as a positive hit. Interestingly, this flavanone compound: inhibits necroptosis induced by death receptors ligands TNF-α (Tumor Necrosis Factor) or TRAIL (TNF-Related Apoptosis-Inducing Ligand); is an extremely selective inhibitor, among kinases, of human RIPK1 enzymatic activity with a nM Kd; has a non-ATP competitive mode of action and a novel putative binding site; is weakly cytotoxic towards human primary blood leukocytes or retinal pigment epithelial cells at effective concentrations; protects human aortic endothelial cells (HAEC) from cold hypoxia/reoxygenation injury more effectively than necrostatin-1 (Nec-1) and Nec-1s. Altogether, these data demonstrate that 6E11 is a novel potent small molecular inhibitor of RIPK1-driven necroptosis.
format Online
Article
Text
id pubmed-5635128
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-56351282017-10-18 6E11, a highly selective inhibitor of Receptor-Interacting Protein Kinase 1, protects cells against cold hypoxia-reoxygenation injury Delehouzé, C. Leverrier-Penna, S. Le Cann, F. Comte, A. Jacquard-Fevai, M. Delalande, O. Desban, N. Baratte, B. Gallais, I. Faurez, F. Bonnet, M. C. Hauteville, M. Goekjian, P. G. Thuillier, R. Favreau, F. Vandenabeele, P. Hauet, T. Dimanche-Boitrel, M. T. Bach, S. Sci Rep Article Necroptosis is a programmed cell death pathway that has been shown to be of central pathophysiological relevance in multiple disorders (hepatitis, brain and cardiac ischemia, pancreatitis, viral infection and inflammatory diseases). Necroptosis is driven by two serine threonine kinases, RIPK1 (Receptor Interacting Protein Kinase 1) and RIPK3, and a pseudo-kinase MLKL (Mixed Lineage Kinase domain-Like) associated in a multi-protein complex called necrosome. In order to find new inhibitors for use in human therapy, a chemical library containing highly diverse chemical structures was screened using a cell-based assay. The compound 6E11, a natural product derivative, was characterized as a positive hit. Interestingly, this flavanone compound: inhibits necroptosis induced by death receptors ligands TNF-α (Tumor Necrosis Factor) or TRAIL (TNF-Related Apoptosis-Inducing Ligand); is an extremely selective inhibitor, among kinases, of human RIPK1 enzymatic activity with a nM Kd; has a non-ATP competitive mode of action and a novel putative binding site; is weakly cytotoxic towards human primary blood leukocytes or retinal pigment epithelial cells at effective concentrations; protects human aortic endothelial cells (HAEC) from cold hypoxia/reoxygenation injury more effectively than necrostatin-1 (Nec-1) and Nec-1s. Altogether, these data demonstrate that 6E11 is a novel potent small molecular inhibitor of RIPK1-driven necroptosis. Nature Publishing Group UK 2017-10-10 /pmc/articles/PMC5635128/ /pubmed/29018243 http://dx.doi.org/10.1038/s41598-017-12788-4 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Delehouzé, C.
Leverrier-Penna, S.
Le Cann, F.
Comte, A.
Jacquard-Fevai, M.
Delalande, O.
Desban, N.
Baratte, B.
Gallais, I.
Faurez, F.
Bonnet, M. C.
Hauteville, M.
Goekjian, P. G.
Thuillier, R.
Favreau, F.
Vandenabeele, P.
Hauet, T.
Dimanche-Boitrel, M. T.
Bach, S.
6E11, a highly selective inhibitor of Receptor-Interacting Protein Kinase 1, protects cells against cold hypoxia-reoxygenation injury
title 6E11, a highly selective inhibitor of Receptor-Interacting Protein Kinase 1, protects cells against cold hypoxia-reoxygenation injury
title_full 6E11, a highly selective inhibitor of Receptor-Interacting Protein Kinase 1, protects cells against cold hypoxia-reoxygenation injury
title_fullStr 6E11, a highly selective inhibitor of Receptor-Interacting Protein Kinase 1, protects cells against cold hypoxia-reoxygenation injury
title_full_unstemmed 6E11, a highly selective inhibitor of Receptor-Interacting Protein Kinase 1, protects cells against cold hypoxia-reoxygenation injury
title_short 6E11, a highly selective inhibitor of Receptor-Interacting Protein Kinase 1, protects cells against cold hypoxia-reoxygenation injury
title_sort 6e11, a highly selective inhibitor of receptor-interacting protein kinase 1, protects cells against cold hypoxia-reoxygenation injury
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635128/
https://www.ncbi.nlm.nih.gov/pubmed/29018243
http://dx.doi.org/10.1038/s41598-017-12788-4
work_keys_str_mv AT delehouzec 6e11ahighlyselectiveinhibitorofreceptorinteractingproteinkinase1protectscellsagainstcoldhypoxiareoxygenationinjury
AT leverrierpennas 6e11ahighlyselectiveinhibitorofreceptorinteractingproteinkinase1protectscellsagainstcoldhypoxiareoxygenationinjury
AT lecannf 6e11ahighlyselectiveinhibitorofreceptorinteractingproteinkinase1protectscellsagainstcoldhypoxiareoxygenationinjury
AT comtea 6e11ahighlyselectiveinhibitorofreceptorinteractingproteinkinase1protectscellsagainstcoldhypoxiareoxygenationinjury
AT jacquardfevaim 6e11ahighlyselectiveinhibitorofreceptorinteractingproteinkinase1protectscellsagainstcoldhypoxiareoxygenationinjury
AT delalandeo 6e11ahighlyselectiveinhibitorofreceptorinteractingproteinkinase1protectscellsagainstcoldhypoxiareoxygenationinjury
AT desbann 6e11ahighlyselectiveinhibitorofreceptorinteractingproteinkinase1protectscellsagainstcoldhypoxiareoxygenationinjury
AT baratteb 6e11ahighlyselectiveinhibitorofreceptorinteractingproteinkinase1protectscellsagainstcoldhypoxiareoxygenationinjury
AT gallaisi 6e11ahighlyselectiveinhibitorofreceptorinteractingproteinkinase1protectscellsagainstcoldhypoxiareoxygenationinjury
AT faurezf 6e11ahighlyselectiveinhibitorofreceptorinteractingproteinkinase1protectscellsagainstcoldhypoxiareoxygenationinjury
AT bonnetmc 6e11ahighlyselectiveinhibitorofreceptorinteractingproteinkinase1protectscellsagainstcoldhypoxiareoxygenationinjury
AT hautevillem 6e11ahighlyselectiveinhibitorofreceptorinteractingproteinkinase1protectscellsagainstcoldhypoxiareoxygenationinjury
AT goekjianpg 6e11ahighlyselectiveinhibitorofreceptorinteractingproteinkinase1protectscellsagainstcoldhypoxiareoxygenationinjury
AT thuillierr 6e11ahighlyselectiveinhibitorofreceptorinteractingproteinkinase1protectscellsagainstcoldhypoxiareoxygenationinjury
AT favreauf 6e11ahighlyselectiveinhibitorofreceptorinteractingproteinkinase1protectscellsagainstcoldhypoxiareoxygenationinjury
AT vandenabeelep 6e11ahighlyselectiveinhibitorofreceptorinteractingproteinkinase1protectscellsagainstcoldhypoxiareoxygenationinjury
AT hauett 6e11ahighlyselectiveinhibitorofreceptorinteractingproteinkinase1protectscellsagainstcoldhypoxiareoxygenationinjury
AT dimancheboitrelmt 6e11ahighlyselectiveinhibitorofreceptorinteractingproteinkinase1protectscellsagainstcoldhypoxiareoxygenationinjury
AT bachs 6e11ahighlyselectiveinhibitorofreceptorinteractingproteinkinase1protectscellsagainstcoldhypoxiareoxygenationinjury